CD274 and cancer: To date, several immune checkpoint inhibitors have been confirmed by the Food and Drug Administration (FDA), such as PD-L1 inhibitors (atezolizumab, durvalumab, avelumab), which are used to treat cancers by immunotherapy [13,40].